We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Maryland Drugmaker Hit for CGMP Violations, Misbranding
Maryland Drugmaker Hit for CGMP Violations, Misbranding
The FDA issued a warning letter to Maryland-based Izeen Pharma for significant violations of current good manufacturing practices and misbranding of its thyroid tablets.